

CLAIMS

1. Crystalline compound of 2-(1-isopropoxycarbonyloxy- 2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine which has diffraction peaks at diffraction angles (2θ): $11.2 \pm 0.1^\circ$, $14.4 \pm 0.1^\circ$, $15.5 \pm 0.1^\circ$, and $25.3 \pm 0.1^\circ$ in a powder X-ray diffraction pattern.

2. The crystalline compound according to claim 1, which has a purity of not less than 99% as determined based on percentage area obtained by HPLC (high-performance liquid chromatography).

3. The crystalline compound according to claim 1 or 2, which has a melting point in the temperature range of 240 to 246°C (with decomposition) as determined from an endothermic peak in a DSC (differential scanning calorimetry) chart obtained by DSC.

4. A composition comprising the crystalline compound according to any one of claims 1 to 3.

5. The composition according to claim 4, for use as a medicament.

6. The composition according to claim 5, for use as an antiallergic agent.

7. Use of the crystalline composition according to any one of claims 1 to 3, for the production of a pharmaceutical composition.

8. A method for preventing or treating an allergic disease, said method comprising the step of administering the crystalline compound according to any one of claims 1 to 3 to an animal including a human.

9. Use of the crystalline substance according to any one of claims 1 to 3, for the production of an antiallergic agent.